← All trials
NCT05025358
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2021
- Primary completion
- Dec 30, 2023
- Completion date
- Jul 30, 2024
- First posted
- Aug 27, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 76
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Lupeng Pharmaceutical Company LTD.Lead sponsor
- Shantou UniversityStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.